SNIPR 001
Alternative Names: SNIPR-001Latest Information Update: 24 Sep 2024
Price :
$50 *
At a glance
- Originator SNIPR Biome
- Class Antibacterials; Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Escherichia coli infections
- Preclinical Sepsis; Urinary tract infections
Most Recent Events
- 22 Apr 2024 Pharmacodynamics data from preclinical trial in Escherichia coli infections released by SNIPR Biome
- 22 Apr 2024 SNIPR Biome plans phase Ib/IIa trial in Escherichia coli infections (Prevention) in Europe and the United States in 2024 (PO)
- 16 Jan 2024 Preclinical trials in Sepsis in Denmark (IV) (SNIPR Biome pipeline, January 2024)